Vice President Translational Medicine at Pierre Fabre
Alexandre Passioukov leads translational medicine efforts across oncology, CNS and dermatology therapeutic areas at Pierre-Fabre R&D. Previously, Dr. Passioukov was leading translational medicine programs at Roche (Switzerland) with a special focus on immune-oncology drugs. Prior to joining Roche, Alexandre served as Head of Translational Research at EORTC in Brussels, conducting structural translational medicine activities of European clinical research networks.
Alexandre is MD with PhD in biology by Université Catholique de Louvain (UCL), where he was closely involved in the launch of 2 spin-off biotech companies: Coulter Pharma Belgium and Diatos.
From Eligibility to CDx: Developping and Implementing Effective Biomarker Strategies for Immuno-Oncology Trials
- Deep understanding of the tumor and the anti-tumor immune response
- Biomarker strategies and a comprehensive toolkit for biomarker testing